Interview With Dr. Salma Jabbour: An In-depth Look At The PROSPECT Trial Caris Molecular Minute Podcast Series podcast

Artwork

Science Caris Molecular Minute Podcast Series Dr Chadi Nabhan

Innhold levert av Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Caris Molecular Minute Podcast Series « »
Interview with Dr. Salma Jabbour: An In-depth Look at the PROSPECT Trial

11M ago 21:16

Del

MP3•Episoder hjem

Innhold levert av Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial. The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC). For more information, please visit: www.CarisLifeSciences.com

… continue reading

60 episoder

#Science #Caris Molecular Minute Podcast Series #Dr Chadi Nabhan

Artwork

Interview with Dr. Salma Jabbour: An In-depth Look at the PROSPECT Trial

Caris Molecular Minute Podcast Series

published 11M ago

Del

MP3•Episoder hjem

Innhold levert av Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Caris Molecular Minute Podcast Series and Dr. Chadi Nabhan eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial. The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC). For more information, please visit: www.CarisLifeSciences.com

… continue reading

60 episoder

#Science #Caris Molecular Minute Podcast Series #Dr Chadi Nabhan

Alla avsnitt

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema